NCT03458260 2026-03-10Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin LymphomaThe Lymphoma Academic Research OrganisationPhase 2 Completed74 enrolled
NCT02800889 2020-01-29Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory CancerCTI BioPharmaPhase 1 Withdrawn